There is a critical need for new therapies for T-cell lymphomas, and with ongoing trials of mTOR and aurora kinase inhibitors, PI3K inhibitors, and others, new options may be on the horizon.
Mark L. Fuerst
A handful of novel antibody-based therapies may soon emerge for the treatment of acute myeloid leukemia, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.
New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies.
Lenalidomide maintenance significantly improves survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.
A combination of the checkpoint inhibitors nivolumab and ipilimumab continues to demonstrate superior clinical activity vs ipilimumab monotherapy in treatment-naive patients with advanced melanoma.
Adding bortezomib to bendamustine/rituximab significantly improves complete remission rates in previously untreated high-risk follicular lymphoma, according to a new study.
A Web-based application allows for earlier detection of relapse among patients with advanced lung cancer, improving survival by 7 months.
Among breast cancer survivors, black women are far less likely to receive BRCA testing and preventive surgery than white or Hispanic women.
A combination of the endoglin antibody TRC105 and pazopanib shows promising activity in patients with advanced soft-tissue sarcoma, particularly angiosarcoma.